|
1
|
Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart.
|
Circ Res
|
2007
|
2.64
|
|
2
|
Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair.
|
Circ Res
|
2006
|
1.64
|
|
3
|
Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium.
|
J Mol Cell Cardiol
|
2007
|
1.61
|
|
4
|
Evidence for ischemia induced host-derived bone marrow cell mobilization into cardiac allografts.
|
J Mol Cell Cardiol
|
2006
|
1.41
|
|
5
|
Retracted
Myoblast transplantation for cardiac repair: from automyoblast to allomyoblast transplantation.
|
Ann Thorac Surg
|
2008
|
1.39
|
|
6
|
Strategies for directing the differentiation of stem cells into the cardiomyogenic lineage in vitro.
|
Cardiovasc Res
|
2004
|
1.29
|
|
7
|
Diazoxide potentiates mesenchymal stem cell survival via NF-kappaB-dependent miR-146a expression by targeting Fas.
|
Am J Physiol Heart Circ Physiol
|
2010
|
1.20
|
|
8
|
Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair.
|
Circulation
|
2007
|
1.13
|
|
9
|
Cardiac tumorigenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction.
|
Regen Med
|
2011
|
1.08
|
|
10
|
Therapeutic angiogenesis. Devising new strategies based on past experiences.
|
Basic Res Cardiol
|
2003
|
1.07
|
|
11
|
Preconditioning promotes survival and angiomyogenic potential of mesenchymal stem cells in the infarcted heart via NF-kappaB signaling.
|
Antioxid Redox Signal
|
2010
|
1.07
|
|
12
|
Adult stem cells for cardiac repair: a choice between skeletal myoblasts and bone marrow stem cells.
|
Exp Biol Med (Maywood)
|
2006
|
1.03
|
|
13
|
Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells.
|
PLoS One
|
2011
|
1.02
|
|
14
|
Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair.
|
J Mol Cell Cardiol
|
2007
|
1.02
|
|
15
|
Mitochondria-specific transgenic overexpression of connexin-43 simulates preconditioning-induced cytoprotection of stem cells.
|
Cardiovasc Res
|
2010
|
0.98
|
|
16
|
Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1.
|
Eur J Heart Fail
|
2006
|
0.96
|
|
17
|
Nonviral vector-based gene transfection of primary human skeletal myoblasts.
|
Exp Biol Med (Maywood)
|
2007
|
0.89
|
|
18
|
Non-hypoxic stabilization of HIF-Iα during coordinated interaction between Akt and angiopoietin-1 enhances endothelial commitment of bone marrow stem cells.
|
J Mol Med (Berl)
|
2012
|
0.87
|
|
19
|
Cell-based VEGF delivery prevents donor cell apoptosis after transplantation.
|
Ann Thorac Surg
|
2007
|
0.84
|
|
20
|
Therapeutic angiogenesis for treatment of peripheral vascular disease.
|
Growth Factors
|
2004
|
0.84
|
|
21
|
Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector for treatment of hind limb ischemia.
|
J Vasc Surg
|
2004
|
0.83
|
|
22
|
Cell-based ex vivo delivery of angiogenic growth factors for cardiac repair.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.83
|
|
23
|
Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model.
|
Eur J Heart Fail
|
2005
|
0.82
|
|
24
|
Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies.
|
Eur J Heart Fail
|
2006
|
0.81
|
|
25
|
In vitro functional assessment of human skeletal myoblasts after transduction with adenoviral bicistronic vector carrying human VEGF165 and angiopoietin-1.
|
J Heart Lung Transplant
|
2005
|
0.81
|
|
26
|
Dose-dependent effect of aprotinin on aggravated pro-inflammatory cytokines in patients with pulmonary hypertension following cardiopulmonary bypass.
|
Cardiovasc Drugs Ther
|
2003
|
0.81
|
|
27
|
Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.
|
Am J Physiol Heart Circ Physiol
|
2012
|
0.80
|
|
28
|
Myoblast-based cardiac repair: xenomyoblast versus allomyoblast transplantation.
|
J Thorac Cardiovasc Surg
|
2007
|
0.80
|
|
29
|
Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair.
|
Biomaterials
|
2008
|
0.79
|
|
30
|
Neuropeptide y and neuropeptide y y5 receptor interaction restores impaired growth potential of aging bone marrow stromal cells.
|
Rejuvenation Res
|
2011
|
0.78
|
|
31
|
Preconditioning of Human Skeletal Myoblast with Stromal Cell-derived Factor-1α Promotes Cytoprotective Effects against Oxidative and Anoxic Stress.
|
Int J Stem Cells
|
2011
|
0.77
|
|
32
|
High efficiency transduction of human VEGF165 into human skeletal myoblasts: in vitro studies.
|
Exp Mol Med
|
2003
|
0.76
|
|
33
|
Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease.
|
J Cell Mol Med
|
2008
|
0.76
|
|
34
|
Developing "super cells" by modification with super anti-apoptotic factor.
|
J Mol Cell Cardiol
|
2006
|
0.75
|
|
35
|
RE: Heng BC, Tong c: the differentiation status of stem cells and their derivatives: A key consideration in transplantation medicine. ASAIO J 50: 626-627, 2004.
|
ASAIO J
|
2005
|
0.75
|
|
36
|
Immunosuppression and xenotransplantation of cells for cardiac repair.
|
Ann Thorac Surg
|
2004
|
0.75
|
|
37
|
Role of pharmacologically mobilized endogenous bone marrow stem cells for cardiac repair.
|
J Heart Lung Transplant
|
2005
|
0.75
|
|
38
|
Avoiding compliance with histocompatibility dogma using immune privileged cell xenografts.
|
Ann Thorac Surg
|
2003
|
0.75
|
|
39
|
New strategy for cardiac repair: genetically modified skeletal myoblasts.
|
Asian Cardiovasc Thorac Ann
|
2007
|
0.75
|
|
40
|
Cardioprotective effect of des-Aspartate-angiotensin-I (DAA-I) on cytokine gene expression profile in ligation model of myocardial infarction.
|
Life Sci
|
2006
|
0.75
|